Gilead Sciences, Inc.
(NASDAQ : GILD)

( )
GILD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.04%132.060.0%$876.29m
AMGNAmgen, Inc. 1.14%251.891.5%$845.87m
GILDGilead Sciences, Inc. 1.08%64.351.0%$548.24m
VRTXVertex Pharmaceuticals, Inc. 0.05%268.481.9%$484.28m
REGNRegeneron Pharmaceuticals, Inc. 0.60%686.022.6%$435.14m
ILMNIllumina, Inc. -1.96%240.263.3%$312.35m
NVAXNovavax, Inc. -9.46%46.5475.7%$259.68m
BIIBBiogen, Inc. 1.58%202.541.8%$237.70m
BNTXBioNTech SE -5.34%154.500.0%$212.23m
SNSSSunesis Pharmaceuticals, Inc. -4.76%2.000.7%$139.81m
EXASEXACT Sciences Corp. -7.90%47.8917.7%$128.82m
TECHBio-Techne Corp. -2.01%357.174.5%$100.62m
NKTXNkarta, Inc. -3.29%12.350.0%$97.91m
BMRNBioMarin Pharmaceutical, Inc. -1.97%78.784.2%$96.46m
TXG10X Genomics, Inc. -8.12%45.720.0%$92.40m

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.